|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Twenty-nine percent of breast carcinomas demonstrated neu DNA amplification and mRNA overexpression, and there was close correlation between the level of neu mRNA expression and detection of neu gene products by ISH and IHC.
|
1973590 |
1990 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Triple-negative breast cancer (TNBC)--a form of breast cancer in which tumour cells do not express the genes for oestrogen receptor, progesterone receptor and HER2 (also called ERBB2 or NEU)--is a highly aggressive malignancy with limited treatment options.
|
24670641 |
2014 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Triple-negative breast cancer (TNBC)--a form of breast cancer in which tumour cells do not express the genes for oestrogen receptor, progesterone receptor and HER2 (also called ERBB2 or NEU)--is a highly aggressive malignancy with limited treatment options.
|
24670641 |
2014 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Triple-negative breast cancer (TNBC)--a form of breast cancer in which tumour cells do not express the genes for oestrogen receptor, progesterone receptor and HER2 (also called ERBB2 or NEU)--is a highly aggressive malignancy with limited treatment options.
|
24670641 |
2014 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Triple-negative breast cancer (TNBC)--a form of breast cancer in which tumour cells do not express the genes for oestrogen receptor, progesterone receptor and HER2 (also called ERBB2 or NEU)--is a highly aggressive malignancy with limited treatment options.
|
24670641 |
2014 |
|
Carcinoma breast stage IV
|
0.020 |
Biomarker
|
disease |
BEFREE |
Trastuzumab, a monoclonal antibody targeting the HER2/neu protein receptor, is effective in the treatment of metastatic breast cancer and may be useful in the treatment of non-small cell lung cancer (NSCLC).
|
11894014 |
2002 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Trastuzumab is a therapeutic monoclonal antibody that selectively recognizes HER2/neu receptor for targeting breast cancers.
|
28528212 |
2017 |
|
Advanced breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Trastuzumab is a humanized monoclonal antibody that binds to human epidermal growth factor-2 (HER2) and is approved by the US Food and Drug Administration for the treatment of advanced breast cancer that overexpresses HER2/neu protein.
|
11894015 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transgenic BALB-neuT mice vaccinated in late-stage tumor development with a DC vaccine expressing a truncated NEU antigen, IL-I5, and its receptor (DC(Ad.Neu+Ad_mIL-15+Ad.mlL-15Ralpha)) were protected from mammary carcinomas, with 70% of animals tumor-free at 30 weeks compared with none of the animals vaccinated with NEU alone (DC(Ad.Neu)).
|
20086176 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TP53 gene alterations were more frequently present in estrogen receptor (ER)-negative (ER-) tumors (P = 0.04) and in tumors with an amplified HER2/NEU oncogene (P = 0.03).
|
8814449 |
1996 |
|
Malignant neoplasm of breast
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Towards this aim, epigenetic editing was performed to suppress HER2/neu expression by inducing epigenetic silencing marks on the HER2/neu promoter.HER2/neu expression and HER2/neu promoter epigenetic modification status were determined in a panel of ovarian and breast cancer cell lines.
|
23814024 |
2013 |
|
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Towards this aim, epigenetic editing was performed to suppress HER2/neu expression by inducing epigenetic silencing marks on the HER2/neu promoter.HER2/neu expression and HER2/neu promoter epigenetic modification status were determined in a panel of ovarian and breast cancer cell lines.
|
23814024 |
2013 |
|
Ewing's sarcoma of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To validate the expression of HER2/neu in these tumors, archival cases of OS (n = 66) and EWS (n = 11) from 44 patients were assessed for HER2/neu gene expression by immunohistochemistry (DAKO rabbit polyclonal antibody A0485).
|
11895910 |
2002 |
|
Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To validate the expression of HER2/neu in these tumors, archival cases of OS (n = 66) and EWS (n = 11) from 44 patients were assessed for HER2/neu gene expression by immunohistochemistry (DAKO rabbit polyclonal antibody A0485).
|
11895910 |
2002 |
|
Osteosarcoma of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To validate the expression of HER2/neu in these tumors, archival cases of OS (n = 66) and EWS (n = 11) from 44 patients were assessed for HER2/neu gene expression by immunohistochemistry (DAKO rabbit polyclonal antibody A0485).
|
11895910 |
2002 |
|
Childhood Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To validate the expression of HER2/neu in these tumors, archival cases of OS (n = 66) and EWS (n = 11) from 44 patients were assessed for HER2/neu gene expression by immunohistochemistry (DAKO rabbit polyclonal antibody A0485).
|
11895910 |
2002 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate whether overexpression of the neu protein in breast tumors differentiates risk factor patterns for breast cancer, neu protein overexpression was determined in 296 breast carcinomas of patients participating in an ongoing population-based case-control study.
|
1348449 |
1992 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate whether overexpression of the neu protein in breast tumors differentiates risk factor patterns for breast cancer, neu protein overexpression was determined in 296 breast carcinomas of patients participating in an ongoing population-based case-control study.
|
1348449 |
1992 |
|
Mammary Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
To investigate whether overexpression of the neu protein in breast tumors differentiates risk factor patterns for breast cancer, neu protein overexpression was determined in 296 breast carcinomas of patients participating in an ongoing population-based case-control study.
|
1348449 |
1992 |
|
Malignant neoplasm of lung
|
0.050 |
Biomarker
|
disease |
BEFREE |
To investigate the potential role of the c-erbB-2/neu gene in lung cancer metastasis systematically, we introduced the human c-erbB-2/neu gene into very low p185neu-expressing NCI-H460 human non-small cell lung cancer cells and then examined the experimental metastatic potentials among the parental NCI-H460 cells and stable transfectants with increased expression of p185neu.
|
7911396 |
1994 |
|
Carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
To investigate the potential role of the c-erbB-2/neu gene in lung cancer metastasis systematically, we introduced the human c-erbB-2/neu gene into very low p185neu-expressing NCI-H460 human non-small cell lung cancer cells and then examined the experimental metastatic potentials among the parental NCI-H460 cells and stable transfectants with increased expression of p185neu.
|
7911396 |
1994 |
|
Primary malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
To investigate the potential role of the c-erbB-2/neu gene in lung cancer metastasis systematically, we introduced the human c-erbB-2/neu gene into very low p185neu-expressing NCI-H460 human non-small cell lung cancer cells and then examined the experimental metastatic potentials among the parental NCI-H460 cells and stable transfectants with increased expression of p185neu.
|
7911396 |
1994 |
|
Cystadenocarcinoma, Serous
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
To correlate with HER2 protein heterogeneity, we investigated the heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma.
|
24123408 |
2013 |
|
Ovarian adenocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrates tumor cell heterogeneity with regard to neu gene amplification and expression in an ovarian adenocarcinoma, reveals the overexpression of novel neu-complementary transcripts in two independently isolated ovarian adenocarcinoma cell lines, and suggests that neu gene expression is not required for intraperitoneal tumorigenicity of ovarian carcinoma xenografts in a nude mouse model system.
|
1346236 |
1992 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study demonstrates tumor cell heterogeneity with regard to neu gene amplification and expression in an ovarian adenocarcinoma, reveals the overexpression of novel neu-complementary transcripts in two independently isolated ovarian adenocarcinoma cell lines, and suggests that neu gene expression is not required for intraperitoneal tumorigenicity of ovarian carcinoma xenografts in a nude mouse model system.
|
1346236 |
1992 |